An experimental single-dose, intranasal influenza vaccine candidate, was found safe and produced a durable immune response when tested in a Phase 1 study, announced the National Institutes of Health.
This study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and published in the Journal of Clinical Investigation on February 2, 2021.
Read More
